ICCM — Icecure Medical Share News
0.000.00%
Last trade - 00:00- $3.56m
- -$8.47m
- $3.38m
IceCure Medical's prelim 2025 revenue misses expectations
Brief: IceCure Medical Entered Into Amendment To Equity Distribution Agreement
Brief: Icecure Reports Financial & Operational Results For The Nine Months Ended September 30, 2025
Brief: Icecure's Prosense® Cryoablation System Receives Regulatory Approval In Switzerland For Indications Including Breast, Lung, Liver, And Kidney Cancer
Brief: IceCure Medical Announces Receipt Of Nasdaq Minimum Bid Price Notification
Brief: IceCure Medical Receives Israeli Approval For Next-Gen XSense Cryoablation System For Breast Cancer, Other Indications
Brief: IceCure Medical Ltd Files For Mixed Shelf Offering Of Up To $100 Million
Icecure Medical Ltd reports results for the quarter ended June 30 - Earnings Summary
Icecure Medical Ltd expected to post a loss of 6 cents a share - Earnings Preview
Icecure Medical Ltd expected to post a loss of 6 cents a share - Earnings Preview
Brief: Icecure Medical Announces Expiration And Results Of Approximately Two Times Over-Subscribed Rights Offering For Aggregate Gross Proceeds Of $10.0 Million
Icecure Medical Ltd reports results for the quarter ended March 31 - Earnings Summary
Icecure Medical Ltd expected to post a loss of 8 cents a share - Earnings Preview
Brief: Icecure Medical FY Gross Margin 44%
Brief: IceCure's ICESECRET Kidney Cancer Cryoablation Study Interim Results Presented at European Association of Urology Conference in Spain: 88.7% Recurrence-Free Rate
IceCure Medical falls after FDA delays decision on breast cancer treatment system
Brief: Icecure Medical Regains Full Nasdaq Compliance With Nasdaq Minimum Closing Bid Price Rule
Brief: IceCure's ProSense® Cryoablation Safe and Effective in Destruction of Kidney Tumors with 88.7% Recurrence-Free Rate Based on Interim ICESECRET Study Results
Brief: Icecure's Next-Generation Multiprobe Cryoablation Technology Issued Notice Of Allowance From Japan's Patent Office